We are a microbiome therapeutics platform company developing a novel class of biological drugs, which are designed to treat disease by
restoring the function of a dysbiotic microbiome. Our lead product candidate, SER-109, is designed to prevent further recurrences of Clostridium difficile infection, or CDI, a debilitating infection of the colon, by treating the dysbiosis of the
colonic microbiome and, if approved by the U.S. Food and Drug Administration, or FDA, could be a first-in-field oral drug. Using our microbiome therapeutics platform, we are developing additional product candidates to treat diseases where the
microbiome is implicated, including SER-262, a synthetic product candidate, to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease, including ulcerative colitis, SER-301, a synthetic inflammatory bowel disease
candidate, and SER-155, a synthetic product candidate, to prevent mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to infections and graft-versus-host disease. We are also using our microbiome therapeutics
platform to conduct research on metabolic diseases, such as non-alcoholic steatohepatitis (NASH); inflammatory diseases, such as Crohns disease; rare liver disorders such as primary sclerosing cholangitis (PSC); and immuno-oncology treatments.
We filed our certificate of incorporation with the Secretary of State of Delaware on October 18, 2010. Our principal executive
offices are located at 200 Sidney Street - 4th Floor, Cambridge, MA 02139, and our telephone number is (617) 945-9626.